Table 3.
Association between Hard Drug Use and Risk of AIDS Progression or Death based on Cox Models for Time to Event
Recent Substance Use at Entry1 | Adjusted Hazard Ratio2 | 95% Confidence Interval | P-value |
---|---|---|---|
Without adjusting for non-adherence: | |||
Recent Hard Drug Use (Cocaine, Heroin, or Amphetamine) | 2.46 | (1.06, 5.69) | 0.04 |
Baseline Viral Load > 500 copies/mL | 2.12 | (1.38, 3.26) | <0.001 |
Karnofsky Score ≤ 80 | 2.01 | (1.23, 3.28) | 0.005 |
Adjusting for non-adherence reported at study entry: | |||
Recent Hard Drug Use (Cocaine, Heroin, or Amphetamine) | 2.58 | (1.11, 5.97) | 0.03 |
Baseline Viral Load > 500 copies/mL | 2.14 | (1.39, 3.30) | <0.001 |
Karnofsky Score ≤ 80 | 2.07 | (1.27, 3.39) | 0.004 |
Non-adherence reported at entry | 0.78 | (0.50, 1.21) | 0.26 |
Adjusting for non-adherence reported throughout study follow-up as time-dependent covariate: | |||
Recent Hard Drug Use (Cocaine, Heroin, or Amphetamine) | 2.11 | (0.90, 4.92) | 0.08 |
Baseline Viral Load > 500 copies/mL | 1.92 | (1.24, 2.97) | 0.003 |
Karnofsky Score ≤ 80 | 1.93 | (1.18, 3.15) | 0.01 |
Time-updated Non-Adherence | 1.84 | (1.15, 2.94) | 0.01 |
Defined as reported use in the 30 days prior to study entry.
We adjusted for baseline HIV RNA>500 copies/ml and Karnofsky score only since all other covariates (age, sex, baseline CD4, non-white status, randomized treatment status [azithromycin versus placebo], years on antiretroviral therapy at entry, and prior AIDS defining event) had p>0.20 or higher.